FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to drugs, and concerns a method for preparing a tabletted pharmaceutical composition. For this purpose, an active pharmaceutical ingredient of formula 
being a receptor NK1 antagonist, or its pharmaceutically acceptable acid addition salts, and a water-soluble poloxamer are processed together by hot melt extrusion before mixing with the other ingredients.
EFFECT: hot melt extrusion with the single ingredients being the active ingredient of formula I and the water-soluble poloxamer provides producing a microcrystalline solid dispersion which when mixed with the other ingredients enables to prepare a tablet exhibiting the solubility characteristics necessary for drug bioavailability.
14 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF 3-PHENYLPYRIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2236402C2 |
| PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
| APPLICATION OF RECEPTOR NK-1 ANTAGONISTS FOR TREATING CRANIOCEREBRAL AND SPINAL TRAUMAS OR NERVOUS TISSUE LESION | 2002 |
|
RU2304435C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2010 |
|
RU2577700C2 |
| PROLONGED-RELEASE COMPOSITION, CONTAINING PEPTIDES AS ACTIVE INGREDIENTS | 2012 |
|
RU2633483C2 |
| PHARMACEUTICAL COMPOSITION FOR ACID LIPOPHILIC COMPOUNDS IN FORM OF SELF-EMULSIFYING COMPOSITION | 1998 |
|
RU2202346C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND | 2008 |
|
RU2488398C2 |
| SELF-EMULSIFYING COMPOSITION FOR LIPOPHILIC COMPOUNDS | 1998 |
|
RU2203648C2 |
